Azenta’s second quarter showed strong momentum, with results surpassing Wall Street’s expectations for both revenue and earnings. Management attributed this outperformance to robust growth in its biorepositories and consumables and instruments (C&I) segments, which are recurring revenue businesses, alongside improved execution in Multiomics, particularly in Europe and China. CEO John Marotta highlighted, “Revenue exceeded our outlook, profitability improved sequentially and Multiomics delivered year-over-year growth,” noting that ongoing operational transformation in Sample Management Solutions played a key role in stabilizing performance.
Is now the time to buy AZTA? Find out in our full research report (it’s free for active Edge members).
Azenta (AZTA) Q2 CY2026 Highlights:
- Revenue: $161.2 million vs analyst estimates of $149.2 million (12% year-on-year growth, 8% beat)
- Adjusted EPS: $0.16 vs analyst estimates of $0.10 (60% beat)
- Adjusted EBITDA: $18.46 million vs analyst estimates of $16.4 million (11.5% margin, 12.6% beat)
- Operating Margin: -2.6%, down from -1.3% in the same quarter last year
- Market Capitalization: $1.46 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Azenta’s Q2 Earnings Call
- David Saxon (Needham): Asked about drivers of Multiomics improvement in North America; CEO John Marotta cited delayed project catch-up, new sales leadership, and stronger commercial execution, while CFO Lawrence Lin stressed the need for more evidence of sustained recovery.
- Matthew Stanton (Jefferies): Inquired about order trends and demand durability; Marotta described strong growth in China and Europe, but noted ongoing lumpiness and headwinds in North America, especially in capital equipment and Sanger sequencing.
- Steven Etoch (Stephens): Probed on capital equipment order conversion; Marotta explained that capacity expansion and standardization are key, with productivity gains being a major driver for client decisions amid ongoing market uncertainty.
- Paul Knight (KeyBanc): Questioned the modular transition in stores; Marotta detailed the move from customized to configurable systems, emphasizing standardization to reduce risk and improve quality.
- Brendan Smith (TD Cowen): Asked about capital allocation and M&A; Marotta reiterated a disciplined approach, balancing share repurchases with strategic acquisitions, and focusing on operational improvements in core businesses.
Catalysts in Upcoming Quarters
In the next few quarters, our analysts will closely monitor (1) the pace at which recurring revenue businesses like biorepositories and C&I sustain their momentum, (2) tangible improvements in Multiomics execution, especially in North America, and (3) the conversion of interest in automated stores into firm orders. The effects of ongoing cost optimization and restructuring efforts will also be key indicators of progress.
Azenta currently trades at $33.33, up from $30.13 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
